Stock Picks Today: IndusInd Bank, Torrent Pharma, GAIL Among Others On Brokerages’ Radar
Check out the latest stock picks and analyst calls from top brokerages on Indian stocks like IndusInd Bank, Torrent Pharma, GAIL, and more.
Blog
Blog
Torrent Pharma Q1 Review: Citi Hikes Target Price — Here’s Why
Citi Research has increased the price target for Torrent Pharmaceuticals Ltd. to Rs 4,380 from Rs 4,000, citing a healthy and in-line quarter and solid traction across the markets. The brokerage maintains a ‘buy’ rating for the firm.
Blog
Indian Rupee Weakens to 86.83 Against US Dollar: What’s Behind the Slide?
The Indian rupee has weakened to 86.83 against the US dollar, marking its lowest level since June 19. What’s driving the slide and what does it mean for Indian investors and traders?
Blog
Top 5 Indian Stocks to Buy: Cartrade Tech, Cipla, Vijay Diagnostic Centre, Fortis Healthcare, Dabur India
Discover the top 5 Indian stocks to buy, as recommended by analysts from IDBI Cap, Kushbohra.com, and JM Financial. Learn about Cartrade Tech, Cipla, Vijay Diagnostic Centre, Fortis Healthcare, and Dabur India.
Blog
Torrent Pharma Share Price Hits New High After Citi Hikes Price Target Following Q1 Results
Shares of Torrent Pharmaceutical Ltd. surged to a record high after the company reported a 20% jump in its quarterly profit and Citi Research increased its price target.
Blog
Mazagon Dock Share Price: A Deep Dive into the Q1 Earnings Miss and Market Impact
Mazagon Dock Shipbuilders’ share price slumps to a three-month low as the company misses net profit estimates. Dive into the Q1 earnings report and explore the market implications.
Blog
NTPC Green Energy Shares Swing After Q1 Profit Surges Almost 60%: A Closer Look at the Earnings
NTPC Green Energy shares experienced a sharp intraday fluctuation after the release of its first-quarter earnings for FY26. The company’s robust set of numbers led to an initial rise of 2.35%, but later pared gains to trade 0.40% lower.
Blog
Ajanta Pharma Posed To Deliver Double Digit Growth: Systematix Reiterates ‘Buy’ Post Strong Q1 Results
Ajanta Pharma Ltd.’s Q1 FY26 revenue surged 13.8% YoY and 11.3% QoQ, driven by strong growth in North America and India branded formulation. Systematix maintains a ‘Buy’ rating with a target price of Rs 3,293.
Blog
SAIL’s Q1 Profit Dip: A One-Time Accounting Hit, CMD Remains Confident of 8% FY26 Growth
Amarendu Prakash, chairman and managing director of SAIL, highlights that the quarterly dip was on the back of planned maintenance activities at plants, calling it a one-time accounting hit. He remains confident of achieving 8% growth for financial year 2026 over 2025.
Blog
Hindustan Aeronautics Can Rally 32%: Anand Rathi Initiates Coverage with ‘Buy’ Recommendation
Anand Rathi initiates coverage on Hindustan Aeronautics Ltd. with a ‘Buy’ recommendation, citing the company’s strong order book, awarding pipeline, and clean balance sheet. The brokerage firm expects the stock to rally 32% and quotes a target price of ₹5,950.